Abstract
New software for the cell separators A 201 and CS 3000 Plus have been developed by Baxter. Fresenius recently offered a single needle option for the AS 104 device. The results of separation are described with respect to total platelet yield, efficiency and cell contamination of the platelet concentrate (PC). Two software programs were evaluated in both the A 201 (version 5.12 and 5.13) and AS 104 cell separators (version 4560 with different separation parameters according to protocol IV and V). With software version 5.12, the A 201 collected 2.0 ± 0.9 × 10 11 platelets in 200 mL plasma whereas 2.3 ± 0.7 × 10 11 platelets could be harvested with version 5.13. The separation efficiencies were 32.1 ± 11.6 and 34.7 ± 10.7%, respectively. The leucocyte contamination was 5.6 ± 4.6 × 10 8 with software version 5.12 and 4.9 ± 7.6 × 10 8 with the 5.13 version. With the CS 3000 Plus cell separator, 2.9 ± 0.8 × 10 11 platelets (efficiency 38.4 ± 8.2%) could be harvested in 208 ± 2 mL plasma. The white blood cell contamination was extremely low (1.4 ± 3.2 × 10 6). There was a high separation efficacy with the Fresenius single needle procedure of 59.1 ± 10.6% (protocol IV) and 58.7 ± 7.3% (protocol V), respectively. The total number of platelets sampled in 338 ± 21 mL plasma was 3.1 ± 0.8 × 10 11 in protocol IV. While 2.8 ± 0.7 × 10 11 thrombocytes were collected in 265 ± 16 mL plasma with protocol V. The leucocyte contamination of these procedures was 7.0 ± 7.0 × 10 6 (protocol IV) and 2.0 ± 1.8 × 10 7 (protocol V).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.